The DOI matches its Crossref record; 138 of the 141 references it cites were found in a registry or an index; none of the 97 sources its claims cite is checked for support yet.
The emerging role of glucagon-like peptide 1 in binge eating
Open accessAbstract
Binge eating is a central component of two clinical eating disorders: binge eating disorder and bulimia nervosa. However, the large treatment gap highlights the need to identify other strategies to decrease binge eating. Novel pharmacotherapies may be one such approach. Glucagon-like peptide-1 (GLP-1) is an intestinal and brain-derived neuroendocrine signal with a critical role in promoting glycemic control through its incretin effect. Additionally, the energy balance effects of GLP-1 are well-established; activation of the GLP-1 receptor (GLP-1R) reduces food intake and body weight. Aligned with these beneficial metabolic effects, there are GLP-1R agonists that are currently used for the treatment of diabetes and obesity. A growing body of literature suggests that GLP-1 may also play an important role in binge eating. Dysregulation of the endogenous GLP-1 system is associated with binge eating in non-human animal models, and GLP-1R agonists may be a promising approach to suppress the overconsumption that occurs during binge eating. Here, we briefly discuss the role of GLP-1 in normal energy intake and reward and then review the emerging evidence suggesting that disruptions to GLP-1 signaling are associated with binge eating. We also consider the potential utility of GLP-1-based pharmacotherapies for reducing binge eating behavior.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 81 Not checked · 20 Own results and interpretations
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“suggesting the physiological relevance of mesolimbic GLP-1R for influencing binge feeding.”
§ The emerging role of glucagon-like peptide-1 in binge eating > 3.1.1 Pharmacological GLP-1R activation and binge-like eating-Interest in
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Animal models cannot fully recapitulate the complexity of human eating disorders, particularly psychological aspects of these disorders”
§ The emerging role of glucagon-like peptide-1 in binge eating > 3.1 Binge-like eating and GLP-1: animal studies
What the sources say
- Not checked yetcites Berner et al., 2020
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“one study using a GLP-1/ estrogen conjugate showed increased efficacy of the conjugate in reducing binge-like eating in ovariectomized mice compared to the suppression of this behavior produced by GLP-1 alone”
§ The emerging role of glucagon-like peptide-1 in binge eating > 3.1.1 Pharmacological GLP-1R activation and binge-like eating-Interest in
What the sources say
- Not checked yetcites Cao et al., 2014
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“GLP-1R agonists have been shown to decrease self-administration of and motivation for substances including alcohol”
§ The emerging role of glucagon-like peptide-1 in binge eating > 2. Glucagon-like peptide-1 2.1 What is GLP-1?
What the sources say
- Not checked yetcites Sorensen et al., 2016
- Not checked yetcites Schmidt et al., 2016
- Not checked yetcites Douton et al., 2022b
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“systemic administration of GLP-1 reduced intake of a sucrose solution in mice given intermittent access to this palatable fluid (Yamaguchi et al., 2017).”
§ The emerging role of glucagon-like peptide-1 in binge eating > 3.1.1 Pharmacological GLP-1R activation and binge-like eating-Interest in
What the sources say
- Not checked yetcites Yamaguchi et al., 2017
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
69 more claims
Create a free account to see all 101 claims and to verify the 97 references still open.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 19
- The quote only partly states this claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Many people who reduce their weight on GLP‐1s experience improved mood, including fewer depressive symptoms [130, 132, 133].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [130]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Many people who reduce their weight on GLP-1s experience improved mood [122,124].”
From Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society (2025) · cites this paper as [122]
Experimental — accuracy not yet measuredIn the citing paper
“Many people who reduce their weight on GLP-1s experience improved mood, including fewer depressive symptoms [130,132,133].”
Citations
Cites
International Journal of Molecular Sciences
(2024) · International Journal of Molecular Sciences · doi:10.3390/ijms · Cited by 10,111
The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication
Hudson, J. I., Hiripi, E., Pope, H. G., & Kessler, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.040 · Cited by 4,973
THE AMERICAN JOURNAL OF PSYCHIATRY: 1844-1944
DUNTON, W. R. (1944) · American Journal of Psychiatry · doi:10.1176/ajp.100.6.45 · Cited by 3,784
Neurobiology of addiction: a neurocircuitry analysis
Koob, G. F., & Volkow, N. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00104-8 · Cited by 3,698
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Alcoholism: Clinical and Experimental Research
(2010) · Alcoholism Clinical and Experimental Research · doi:10.1111/(issn)1530-0277 · Cited by 1,831
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
International Journal of Eating Disorders
(2006) · doi:10.1002/(issn)1098-108x · Cited by 1,147
British Journal of Pharmacology
(2010) · British Journal of Pharmacology · doi:10.1111/(issn)1476-5381 · Cited by 920
Obesity Management in Adults: A Review
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 813
Cited by
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“Many people who reduce their weight on GLP-1s experience improved mood [122,124].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
“Many people who reduce their weight on GLP-1s experience improved mood, including fewer depressive symptoms [130, 132, 133].”
GLP-1 and Its Analogs: Does Sex Matter?
Börchers, S., & Skibicka, K. P. (2024) · Endocrinology · doi:10.1210/endocr/bqae165 · Cited by 108
Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events
He, L., Li, Q., Yang, Y., Li, J., Luo, W., Huang, Y., & Zhong, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1416985 · Cited by 40
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 41
Metadata
- Authors
- Balantekin, K. N., Kretz, M. J., & Mietlicki-Baase, E. G.
- Affiliations
- University at Buffalo, State University of New York (US)
- Department of Exercise and Nutrition Sciences, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York, USA
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2024-04-17
- Volume
- 262
- Issue
- 1
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- PMC
- PMC11156433
- OpenAlex
- W4394877548
- Cited by
- 38
- References
- 141
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 4
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK120778, R01DK128030)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- glucagon-like peptide-1, binge eating, binge eating disorder, bulimia nervosa, GLP-1 receptor agonists, GLP-1 signaling, energy balance, food intake regulation, food reward
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Bulimia, Energy Intake, Energy Metabolism, Humans, Glucagon-Like Peptide 1, Binge-Eating Disorder
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The emerging role of glucagon-like peptide 1 in binge eating. https://app.cochat.ai/papers/10.1530/joe-23-0405
- The paper
- Balantekin, K. N., Kretz, M. J., & Mietlicki-Baase, E. G. (2024). The emerging role of glucagon-like peptide 1 in binge eating. Journal of Endocrinology. https://doi.org/10.1530/joe-23-0405
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.